Get the latest Venture Capital & Angel investors news and info Join Our Mailing List:

Your Name: 

Your Email:  

*By submitting your name & email you agree to receive for FREE our scholarships & offers Newsletters. You agree also with the storage and handling of your data by this website and 3rd party email services.
You may unsubscribe if you wish. And you can delete your email and name at any time by emailing us to the email on the bottom of this page.

Follow us on
  • Amira Pharmaceuticals Raises $25 Million in Series B Financing

    March 26th, 2007 No comments

    Amira Pharmaceuticals, a privately-held biopharmaceutical company focused on developing new drugs to treat inflammatory disease, recently announced that it has raised $25 million in a private equity financing led by Novo A/S. Additional investors in the Series B round included Avalon Ventures, Prospect Venture Partners and Versant Ventures, all founding investors.

    With the completion of this financing round, Amira has raised a total of $40 million since the company’s inception two years ago.

    The additional funding will enable the company to advance multiple drug candidates through clinical proof of concept, including AM103 to treat respiratory and cardiovascular conditions. An Investigational Medicinal Product Dossier (IMPD) for AM103 is expected to be filed in Europe within the next two months.

    AM103 was discovered by the Amira team and has two back-up compounds in the final stages of preclinical development. The respiratory market alone for each of these compounds is estimated to be between USD 2-3 billion. Discussions are underway with several potential pharmaceutical partners.

    Peppi Prasit, Ph.D., Chief Scientific Officer of Amira, said: “The new investment from Novo, alongside the valued support of our founding investors, will allow us to reach clinically meaningful results in several programs within a short period of time.

    “We have already achieved a lot in terms of discovery – now it’s time for our development program to investigate the potential for these novel medicines, several of which have the potential to be best-in-class blockbuster treatments.“

    “We are very impressed with the successful track record and continued ability of the drug hunters at Amira,” said Heath Lukatch, Ph.D., Novo Partner and new member of Amira’s Board of Directors. “This is a team who was pivotal in the discovery of three major drugs while previously at Merck & Co (Singulair, Vioxx, and Arcoxia) and they have proved they can go beyond those discoveries to create the potentially significant medicines of the future. It is extraordinary to have achieved so much in two years and we appreciate the opportunity to support them at a crucial time in the company’s development.”

    As a result of the financing, Heath Lukatch will join the Amira Board, alongside Bradley Bolzon of Versant Ventures, Kevin Kinsella of Avalon Ventures,  James Tananbaum of Prospect Venture Partners and Peppi Prasit, a co-founder of Amira.

    Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a privately-held biopharmaceutical company, focused on inflammatory disease.

    The founding team at Amira has over 100 combined years of experience in drug discovery, which includes the development of marketed drugs for a variety of indications. Its scientific founders have successfully worked together for over a decade.

    In January 2006, Amira signed a collaboration agreement with Roche covering a research alliance and an option for Amira to license two clinical-stage compounds from Roche.

    For more information, visit

Leave a reply

Please leave these two fields as-is:

Protected by Invisible Defender. Showed 403 to 266,618 bad guys.


Latest Headlines:

Friday August 31, 2012
Zscaler Secures $38 Million Investment Round

Wednesday November 30, 2011
Health Care Solutions companies Infinity Pharmaceutics, NanoVobronix and Selventa raise funds.

Monday November 21, 2011
Panda Power opens $420 Million Fund for Solar and Natural Gas Projects

Thursday November 17, 2011
Better Place raises $200 Million for Electric Cars in the Series C of Funding

Wednesday November 16, 2011
Accel Partners raise $100 Million Big Data Fund to Invest in Hadoop, NoSQL and other Companies

Tuesday November 15, 2011
Skimlinks raises $4.5 Million to help Bloggers Increase their Gains

Monday November 14, 2011
Standing Cloud raises $3 Million to help New Cloud Providers grow Faster

Thursday November 10, 2011
Zillow acquires Diverse Solutions for $7.8 to help Real Estate Agents increase their Visibility


By using this website you agree with our cookie policy